Scientists Just Took a Big Step Toward Ending the Opioid Epidemic

A new pain medication appears to be less dangerous than the prescription drugs that are killing thousands—and not addictive.

<a href="http://www.istockphoto.com/photo/oxycontin-bottle-on-shelf-gm578596836-99485787?st=_p_oxycontin">Pureradiancephoto</a>/iStock

Facts matter: Sign up for the free Mother Jones Daily newsletter. Support our nonprofit reporting. Subscribe to our print magazine.


Scientists are one step closer to designing a drug that relieves pain but doesn’t have the harmful side effects of today’s opioid painkillers.

When the rodents treated with the compound were placed on a hot plate, they appeared to experience as much pain relief as those treated with morphine.

The need is clear: In 2014, 14,000 Americans died from overdoses involving prescription opioids like oxycodone or hydrocodone (known by brand names OxyContin and Vicodin). The death toll from prescription opioid overdoses has roughly quadrupled since 1999. The drugs, prescribed for chronic pain, frequently lead to addiction; as many as one in four people prescribed opioids for long-term pain struggles with addiction, according to the Centers for Disease Control. When ingested in high doses, the drugs slow down breathing and can be fatal.

A team of researchers, whose work was published earlier this month in Nature, designed a compound named PZM21 that is producing promising results. Multiple experiments on mice appear to reduce pain without slowing down breathing or being addictive. When the rodents treated with the compound were placed on a hot plate, for example, they appeared to experience as much pain relief as those treated with morphine. Mice showed no preference between being in a chamber where they received PMZ21 and another where they received a saline solution.

Rather than tweaking an existing drug, as most drugs are created, the research team used a combination of computational modeling and synthetic drug generation to design a compound from scratch that would bind well with the known structure of the brain’s opioid receptors. Doing so was a four-year effort, involving researchers from Stanford University, the University of North Carolina at Chapel Hill, the University of California-San Francisco, and Friedrich-Alexander University in Germany.

Of course, there’s a long way between mice studies and a drug on the market for human use; the authors estimate it will be one to two years until the compound makes its way to the Food and Drug Administration for testing. Still, when it comes to developing a drug that could help mitigate today’s opioid crisis, Aashish Manglik, a Stanford physiologist and the study’s lead author, says he is “cautiously optimistic.”

THE END...

of our fiscal year is Thursday, June 30, and we have a much larger fundraising gap than we can easily manage with only days left to go.

Right now is no time to come up short: If you value the hard-hitting, democracy-protecting, justice-advancing journalism you get from Mother Jones, please help us keep charging as hard as we possibly can with a much-needed and much-appreciated donation today.

payment methods

THE END...

of our fiscal year is Thursday, June 30, and we have a much larger fundraising gap than we can easily manage with only days left to go.

Right now is no time to come up short: If you value the hard-hitting, democracy-protecting, justice-advancing journalism you get from Mother Jones, please help us keep charging as hard as we possibly can with a much-needed and much-appreciated donation today.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate